HC Wainwright & Co. Downgrades Fulcrum Therapeutics to Neutral, Lowers Price Target to $3
Benzinga Newsdesk 5 months ago
NewsDowngradesPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andrew S. Fein downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Neutral and lowers the price target from $25 to $3.
HC Wainwright & Co. analyst Andrew S. Fein downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Neutral and lowers the price target from $25 to $3.